异柠檬酸脱氢酶抑制剂对急性髓性白血病的精准医疗

Iosocitrate dehydrogenase inhibitors as precision medicine for acute myeloid leukemia

急性髓性白血病(AML)的治疗在过去几十年中有了显著改善,开发了针对与该疾病相关特定基因突变精准治疗的新药物。异柠檬酸脱氢酶(IDH)抑制剂作为其中之一,对具有IDH1或IDH2突变的患者有显著的疗效。本文就IDH抑制剂在AML的精准医疗方面的研究进行综述。

The treatment of acute myeloid leukemia(AML)has improved dramatically over the past decades,with the development of new drugs that target specific genetic mutations associated with the disease.One of these,iosocitrate dehydrogenase(IDH)inhibitors,has achieved significant efficacy for patients with IDH1 or IDH2 mutations.This article reviews the researches on IDH inhibitors as precision medicine for AML.